This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Greatbatch, Inc. Reports 2011 Fourth Quarter And Full Year Results

Greatbatch, Inc. (NYSE: GB), today announced results for its fourth quarter and full year ended December 30, 2011:

  • Sales of $141.7 million for the fourth quarter increased 6% over the prior year, driven by 28% Vascular Access and 27% Electrochem organic revenue growth.
  • Full year 2011 sales of $568.8 million increased 7% over the prior year and included 19% Vascular Access, 11% Orthopaedic and 6% Electrochem organic revenue growth.
  • Fourth quarter sales included approximately $3 million of medical device sales ($5 million Full Year) and $2.5 million of revenue from the acquisition of Micro Power Electronics in December 2011.
  • Fourth quarter GAAP and Adjusted Diluted EPS were $0.24 and $0.39 per share, respectively.
  • Full year GAAP and Adjusted Diluted EPS were $1.40 and $1.68 per share, respectively.
  • Cash flow from operations remained strong at $31 million for the fourth quarter and $90 million for the full year 2011.
  Three months ended
(Dollars in thousands, except EPS data) December 30,   December 31,   %   September 30,   %
2011 2010 Change 2011 Change
Sales $ 141,746 $ 133,111 6% $ 131,718 8%
 
GAAP Operating Income $ 12,542 $ 24,512 -49% $ 12,888 -3%
GAAP Operating Income as % of Sales 8.8% 18.4% 9.8%
 
Adjusted Operating Income* $ 15,748 $ 17,758 -11% $ 14,714 7%
Adjusted Operating Income as % of Sales 11.1% 13.3% 11.2%
 
GAAP Diluted EPS $ 0.24 $ 0.59 -59% $ 0.30 -20%
Adjusted Diluted EPS* $ 0.39 $ 0.46 -15% $ 0.41 -5%
  Year ended
(Dollars in thousands, except EPS data) December 30,   December 31,   %
2011 2010 Change
Sales $ 568,822 $ 533,425 7%
 
GAAP Operating Income $ 61,699 $ 68,994 -11%
GAAP Operating Income as % of Sales 10.8% 12.9%
 
Adjusted Operating Income* $ 67,602 $ 64,937 4%
Adjusted Operating Income as % of Sales 11.9% 12.2%
 
GAAP Diluted EPS $ 1.40 $ 1.40 0%
Adjusted Diluted EPS* $ 1.68 $ 1.51 11%
 
* See Tables A and B at the end of this release for a reconciliation of adjusted amounts to GAAP.

CEO Comments

“Overall, 2011 was a very successful year for Greatbatch,” stated Thomas J. Hook, President & CEO, Greatbatch, Inc. “Our diversified revenue base increased 7% for the year, which included significant growth from our Vascular Access, Orthopaedic and Electrochem product lines, and was achieved despite a contracting CRM market. This sales growth, combined with our strong cash generation and debt reduction, drove an 11% increase in adjusted diluted EPS for the year and continued to fund our medical device initiatives. During 2011, we continued to make significant progress on the development of these devices, and saw the first returns on our investments. Additionally, during 2011 we were able to close on the strategic acquisition of Micro Power Electronics, which provides us with a leadership position within the portable medical market and further diversifies our revenue base. Going forward, we are well positioned to accelerate our growth, as we gain market share in our non-CRM markets, commercialize our medical device projects and benefit from potential acquisitions.”

Stock quotes in this article: GB 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,501.65 0.00 0.00%
S&P 500 1,878.61 +3.22 0.17%
NASDAQ 4,148.3380 +21.3710 0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs